Literature DB >> 16429403

BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension.

Micheala A Aldred1, Jairam Vijayakrishnan, Victoria James, Florent Soubrier, Miguel A Gomez-Sanchez, Gunnar Martensson, Nazzareno Galie, Alessandra Manes, Paul Corris, Gerald Simonneau, Marc Humbert, Nicholas W Morrell, Richard C Trembath.   

Abstract

Mutations of the BMPR2 gene predispose to pulmonary arterial hypertension (PAH), a serious, progressive disease of the pulmonary vascular system. However, despite the fact that most PAH families are consistent with linkage to the BMPR2 locus, sequencing only identifies mutations in some 55% of familial cases and between 10% and 40% of cases without a family history (idiopathic or IPAH). We therefore conducted a systematic analysis for larger gene rearrangements in panels of both familial and idiopathic PAH cases that were negative on sequencing of coding regions. Analysis of exon dosage across the entire gene using Multiplex Ligation-dependent Probe Amplification identified nine novel rearrangements and enabled full characterization at the exon level of previously reported deletions. Overall, BMPR2 rearrangements were identified in 7 of 58 families and 6 of 126 IPAH cases, suggesting that gross rearrangements underlie around 12% of all FPAH cases and 5% of IPAH. Importantly, two deletions encompassed all functional protein domains and are predicted to result in null mutations, providing the strongest support yet that the predominant molecular mechanism for disease predisposition is haploinsufficiency. Dosage analysis should now be considered an integral of part of the molecular work-up of PAH patients. 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16429403     DOI: 10.1002/humu.9398

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  74 in total

Review 1.  Strategic plan for lung vascular research: An NHLBI-ORDR Workshop Report.

Authors:  Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore
Journal:  Am J Respir Crit Care Med       Date:  2010-09-10       Impact factor: 21.405

2.  Evolving Schema for Employing Network Biology Approaches to Understand Pulmonary Hypertension.

Authors:  Shohini Ghosh-Choudhary; Stephen Y Chan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension.

Authors:  Ling Yan; Xinping Chen; Megha Talati; Bethany Womack Nunley; Santhi Gladson; Tom Blackwell; Joy Cogan; Eric Austin; Ferrin Wheeler; James Loyd; James West; Rizwan Hamid
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

4.  The cancer paradigm of severe pulmonary arterial hypertension.

Authors:  Pradeep R Rai; Carlyne D Cool; Judy A C King; Troy Stevens; Nana Burns; Robert A Winn; Michael Kasper; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2008-06-12       Impact factor: 21.405

5.  Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.

Authors:  Yanli Song; Laura Coleman; Jianru Shi; Hideyuki Beppu; Kaori Sato; Kenneth Walsh; Joseph Loscalzo; Ying-Yi Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-13       Impact factor: 4.733

Review 6.  Pulmonary arterial hypertension: the clinical syndrome.

Authors:  Yen-Chun Lai; Karin C Potoka; Hunter C Champion; Ana L Mora; Mark T Gladwin
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

7.  Increased Mutagen Sensitivity and DNA Damage in Pulmonary Arterial Hypertension.

Authors:  Chiara Federici; Kylie M Drake; Christina M Rigelsky; Lauren N McNelly; Sirena L Meade; Suzy A A Comhair; Serpil C Erzurum; Micheala A Aldred
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 8.  Pulmonary arterial hypertension: pathogenesis and clinical management.

Authors:  Thenappan Thenappan; Mark L Ormiston; John J Ryan; Stephen L Archer
Journal:  BMJ       Date:  2018-03-14

9.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

Review 10.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.